IDYA Valuation

IDEAYA Biosciences Inc

Add to Watchlist

Advanced Chart

24.550

-0.38(-1.524%)1D

Overview
Forecast
Valuation
Earnings

IDYA Relative Valuation

IDYA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, IDYA is overvalued; if below, it's undervalued.

Historical Valuation

IDEAYA Biosciences Inc (IDYA) is now in the Fair zone, suggesting that its current forward PS ratio of 120.93 is considered Fairly compared with the five-year average of -10.88. The fair price of IDEAYA Biosciences Inc (IDYA) is between 17.47 to 30.51 according to relative valuation methord.

Relative Value

Fair Zone

17.47-30.51

Current Price：24.93

Fair

-7.41

Trailing

Forward

-3.69

EV/EBITDA

IDEAYA Biosciences Inc. (IDYA) has a current EV/EBITDA of -3.69. The 5-year average EV/EBITDA is -10.08. The thresholds are as follows: Strongly Undervalued below -50.32, Undervalued between -50.32 and -30.20, Fairly Valued between 10.04 and -30.20, Overvalued between 10.04 and 30.16, and Strongly Overvalued above 30.16. The current Forward EV/EBITDA of -3.69 falls within the Historic Trend Line -Fairly Valued range.

-3.49

EV/EBIT

IDEAYA Biosciences Inc. (IDYA) has a current EV/EBIT of -3.49. The 5-year average EV/EBIT is -5.97. The thresholds are as follows: Strongly Undervalued below -15.53, Undervalued between -15.53 and -10.75, Fairly Valued between -1.19 and -10.75, Overvalued between -1.19 and 3.59, and Strongly Overvalued above 3.59. The current Forward EV/EBIT of -3.49 falls within the Historic Trend Line -Fairly Valued range.

120.93

IDEAYA Biosciences Inc. (IDYA) has a current PS of 120.93. The 5-year average PS is 85.35. The thresholds are as follows: Strongly Undervalued below -105.82, Undervalued between -105.82 and -10.23, Fairly Valued between 180.94 and -10.23, Overvalued between 180.94 and 276.53, and Strongly Overvalued above 276.53. The current Forward PS of 120.93 falls within the Historic Trend Line -Fairly Valued range.

-8.29

P/OCF

IDEAYA Biosciences Inc. (IDYA) has a current P/OCF of -8.29. The 5-year average P/OCF is -4.72. The thresholds are as follows: Strongly Undervalued below -71.64, Undervalued between -71.64 and -38.18, Fairly Valued between 28.75 and -38.18, Overvalued between 28.75 and 62.21, and Strongly Overvalued above 62.21. The current Forward P/OCF of -8.29 falls within the Historic Trend Line -Fairly Valued range.

-7.46

P/FCF

IDEAYA Biosciences Inc. (IDYA) has a current P/FCF of -7.46. The 5-year average P/FCF is -8.29. The thresholds are as follows: Strongly Undervalued below -49.89, Undervalued between -49.89 and -29.09, Fairly Valued between 12.50 and -29.09, Overvalued between 12.50 and 33.30, and Strongly Overvalued above 33.30. The current Forward P/FCF of -7.46 falls within the Historic Trend Line -Fairly Valued range.

IDEAYA Biosciences Inc (IDYA) has a current Price-to-Book (P/B) ratio of 2.28. Compared to its 3-year average P/B ratio of 2.67 , the current P/B ratio is approximately -14.73% higher. Relative to its 5-year average P/B ratio of 2.56, the current P/B ratio is about -10.92% higher. IDEAYA Biosciences Inc (IDYA) has a Forward Free Cash Flow (FCF) yield of approximately -13.57%. Compared to its 3-year average FCF yield of -8.81%, the current FCF yield is approximately 53.99% lower. Relative to its 5-year average FCF yield of -5.56% , the current FCF yield is about 143.84% lower.

2.28

P/B

Median3y

2.67

Median5y

2.56

-13.57

FCF Yield

Median3y

-8.81

Median5y

-5.56

Competitors Valuation Multiple

The average P/S ratio for IDYA's competitors is 36.65, providing a benchmark for relative valuation. IDEAYA Biosciences Inc Corp (IDYA) exhibits a P/S ratio of 120.93, which is 229.96% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

IDYA.O

IDEAYA Biosciences Inc

Harmony Biosciences Holdings Inc

Agios Pharmaceuticals Inc

Ocular Therapeutix Inc

Centessa Pharmaceuticals PLC

Loss

2.22B

Performance Decomposition

Market capitalization of IDYA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of IDYA in the past 1 year is driven by Unknown.